Phase I
Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.
Phase 1 data show favourable safety profile
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients.
Initial data from the first cohort expected in first half of 2019
In its recent third-quarter report, Cambridge, Mass.-based Intellia Therapeutics indicated it is delaying its submission of an Investigational New Drug (IND) application until 2020, from late 2019.
The United Kingdom is calling for greater clinical trial transparency after a government committee released a report that indicates that data from about half of all clinical trials in that country are not published, raising concerns over research integrity and risks to human health.
Galapagos NV announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF).
Booster Vaccination After ~7 Years Resulted in 600-fold Increase in Antibody Response
Santhera Pharmaceuticals announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF).
PRESS RELEASES